Glenmark Launches TEVIMBRA in India for Lung & Esophageal Cancers

  Published 9 months ago

Glenmark launches TEVIMBRA in India for NSCLC and ESCC, approved by CDSCO, offering an immune-oncology treatment.

  • TEVIMBRA, developed by BeiGene, treats NSCLC and ESCC in first-line and second-line settings.
  • Glenmark's first immune-oncology product in India, expanding its innovative oncology portfolio.
  • TEVIMBRA demonstrates strong efficacy and safety in global Phase 3 trials for solid tumors.

You might like these

Titan Buys 67% Stake in Damas

Nifty Futures Close Slightly Above Spot

India’s July 2025 Job Market Update

NSDL Lists at 10% Premium on BSE

Landmark Cars Q2 FY26 Revenue Surge

RBI Eases Credit Norms for Infra Bonds

CESC wins 300 MW solar project

News that matters the most ⚡